Skip to content
X-Zell logo

X-Zell

X-Zell is a YC Winter 2015 (W15) company. Based in Singapore, Singapore; Bangkok, Thailand; Düsseldorf, NRW, Germany. Team of 19.

  • Medical Devices

About X-Zell

GPAgent's own fund-neutral profile, written from public information. Updated Oct 4, 2026.

Summary

X-Zell develops a rare cell detection platform that isolates and visualizes abnormal cells, such as Circulating Endothelial Cells, from blood samples. The platform covers every step from blood processing to cell analysis and reporting using patented, proprietary technology. It targets clinical and research applications including early cancer detection, companion diagnostics, medication management, and relapse monitoring, replacing less sensitive or more invasive diagnostic approaches.

From the Y Combinator listing

How X-Zell describes itself in Y Combinator's public directory. Original listing (opens in a new tab)

Early, pain-free cancer detection.

X-ZELL™ is a global start-up specialising in rare cell detection technology. Backed by Y Combinator and various high-profile angel investors from around the globe – among them Gmail creator Paul Buchheit – X-ZELL™ has developed a world-first platform technology capable of isolating and visualizing rare and abnormal cells such as Circulating Endothelial Cells (CEC). X-ZELL™’s platform technology is based on four core modules covering the entire spectrum from blood processing through to cell analysis and reporting – with every step performed in-house using patented and proprietary technology. By combining the wisdom of 4,000 years of pathologic research with X-ZELL™’s own, cutting-edge technology, X-ZELL™ ensures robust results and maximum clinical utility across a broad range of medical applications – from research through to medication management, companions diagnostics, relapse control and diagnostic decision-making. More information on www.x-zell.com and @XZELLInc

Facts

Industry
Healthcare / Healthcare -> Diagnostics
Location
Singapore, Singapore; Bangkok, Thailand; Düsseldorf, NRW, Germany
Team size
19
Status
Active
Stage
Early

Founders (2)

Score every batch against your own thesis

GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.

How Accelerator intelligence works